Erlotinib in the treatment of non-small cell lung cancer
ER Brown, FA Shepherd - Expert review of anticancer therapy, 2005 - Taylor & Francis
Inhibition of the epidermal growth factor receptor is one of the most promising novel
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?
CL Hann, JR Brahmer - Current treatment options in oncology, 2007 - Springer
Opinion statement Inhibition of the epidermal growth factor receptor (EGFR) pathway in non-
small cell lung cancer (NSCLC) is an exciting and rapidly evolving field. Erlotinib and …
small cell lung cancer (NSCLC) is an exciting and rapidly evolving field. Erlotinib and …
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
A Onn, M Tsuboi, N Thatcher - British journal of cancer, 2004 - nature.com
Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related
mortality and, until screening detects early disease, treatment for the majority of patients will …
mortality and, until screening detects early disease, treatment for the majority of patients will …
[PDF][PDF] Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - clf1.medpagetoday.com
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer
A Viswanathan, G Pillot, R Govindan - Lung Cancer, 2005 - lungcancerjournal.info
Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …